-
Psychedelics Co. Champignon Announces New CEO, $10M In Funding And M&A Deal
Wednesday, May 13, 2020 - 7:30am | 621Read More...Psychedelic-focused health company Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) recently made a string of announcements. The company confirmed Dr. Roger McIntyre as its new CEO, a private placement raise of $10 million and the acquisition of a California-based ketamine treatment centre which marks...
-
Tilray Shares Plunge On The Heels Of $90.4M Equity Offering
Friday, March 13, 2020 - 2:13pm | 251Read More...Tilray Inc. (NASDAQ: TLRY) announced Friday that it has priced a $90.4-million equity offering. The Nanaimo, Canada-based company is offering 7.25 million Class 2 shares and, in place of Class 2 shares, pre-funded warrants to buy 11.75 million Class 2 shares and accompanying...
-
Boeing Analyst Slashes Price Target, Says Plane Manufacturer's Outlook Just Got A Lot 'Murkier'
Thursday, March 12, 2020 - 11:39am | 356Read More...The impact of the coronavirus on the airline industry has created a much gloomier outlook for already-struggling Boeing Co (NYSE: BA), according to Canaccord Genuity. The Boeing Analyst Ken Herbert maintained a Hold rating on Boeing and reduced the price target from $340 to $225. The...
-
Canaccord Pumps The Brakes On Tesla Following Stock's Huge Run
Wednesday, February 5, 2020 - 12:50pm | 327Read More...After the massive spike in Tesla Inc’s (NASDAQ: TSLA) stock so far this year, it’s time for investors “to lock in profits,” according to Canaccord Genuity. The Tesla Analyst Jed Dorsheimer downgraded Tesla from Buy to Hold with an unchanged $750 price target. The Tesla...
-
'Leader Of The EV Revolution': 5 Analysts Weigh In On Tesla's Q4 Beat
Thursday, January 30, 2020 - 1:25pm | 802Read More...Tesla Inc (NASDAQ: TSLA) exceeded fourth-quarter earnings expectations with a $2.14 adjusted bottom line and $7.38 billion in revenue. Management closed the quarter with $6.3 billion in cash and $1 billion in free cash flow — $1.1 billion better than Morgan Stanley’s $100 million burn...
-
Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says
Monday, January 27, 2020 - 12:18pm | 403Read More...Despite the controversy surrounding Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug trial results and skepticism concerning its approvability, an analyst at Canaccord Genuity sounds upbeat. The Analyst Sumant Kulkarni upgraded Biogen from Hold to Buy and increased the price target from $305 to...
-
Wall Street Weighs In On Boeing's Latest 737 Max Delay
Wednesday, January 22, 2020 - 1:32pm | 625Read More...Boeing Co (NYSE: BA) shares took a hit this week following reports that the grounded 737 Max won’t be cleared for flight by regulators until June or July. The new timeline is months later than the company had previously targeted. The 737 Max has been grounded by regulators since March of 2019...
-
Apple Gets Another Price Target Hike, Analyst Predicts Strong Services Trends
Wednesday, January 15, 2020 - 1:50pm | 453Read More...On the heels of a price target revision by DA Davidson to a Street-high $375 earlier this week, Canaccord Genuity analyst Michael Walkley maintained a Buy rating on Apple Inc. (NASDAQ: AAPL) and raised his price target from $275 to $355, suggesting roughly 14% upside. Apple's ecosystem approach...
-
Is 2020 The Year Of Uber? 2 Pros Discuss Key Issues
Monday, January 13, 2020 - 2:26pm | 357Read More...Ride-hailing companies could fare well in 2020 but it may be a mistake to assume Uber Technologies Inc (NYSE: UBER) and Lyft Inc (NASDAQ: LYFT) offer similar investment profiles, according to Canaccord Genuity's Michael Graham. Uber Vs. Lyft Graham said Monday on CNBC's "Squawk Box...
-
Canaccord Lifts Tesla Price Target Above $500 Amid International Opportunity
Thursday, January 2, 2020 - 1:50pm | 392Read More...In mid-December, Tesla Inc (NASDAQ: TSLA) broke a previously impenetrable $400 ceiling — and kept climbing. The automaker vindicated patient bulls and prompted some to raise the bar to even more ambitious heights. The Rating Canaccord Genuity analyst Jed Dorsheimer maintained a Buy rating on...
-
Zynerba Analyst Says Stock A Buy Ahead Of Zygel Data Release In 2020
Monday, December 16, 2019 - 6:12pm | 438Read More...Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares ended Monday's session nearly 15% higher after Canaccord Genuity said the stock's mid-September sell-off was unjustified. The Analyst Sumant Kulkarni maintained a Buy rating on Zynerba with an $18 price target. The Thesis The Phase 2...
-
Wall Street Weighs In On Workday's Q3 Earnings
Wednesday, December 4, 2019 - 5:26pm | 658Read More...Workday Inc (NASDAQ: WDAY) shares dropped 4.8% on Wednesday after the company reported third-quarter earnings and revenue beats and raised its full-year subscription revenue guidance. Workday reported $798.5 million in total revenue, up 28% from a year ago and slightly ahead of consensus analyst...
-
Wall Street Is As Bullish As Ever On Salesforce
Wednesday, December 4, 2019 - 11:16am | 676Read More...Salesforce.com, Inc. (NYSE: CRM) shares dipped 3.5% after the company reported third-quarter revenue and earnings ahead of consensus analyst expectations on Tuesday. Revenue performance obligation (RPO) growth guidance of 21% for the fourth quarter came up short of consensus expectations of 23%....
-
Cresco Labs Announces $40M-Plus At-The-Market Offering
Tuesday, December 3, 2019 - 2:56pm | 243Read More...Cresco Labs Inc. (CSE: CL) (OTC: CRLBF) said Tuesday that it has signed an equity distribution agreement with Canaccord Genuity under which the company is authorized to sell up to CA$55 million ($41.3 million) of subordinate voting shares. The company said it plans to use the net proceeds from...
-
The Green Organic Dutchman Announces $16.5M Bought Deal Offering, Stock Falls
Tuesday, November 26, 2019 - 3:38pm | 246Read More...Canadian organic cannabis producer The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF) announced Tuesday that it has signed a bought deal agreement with a syndicate of underwriters led by Canaccord Genuity. The agreement dictates that the underwriters will buy an aggregate of 29,334,000 units at a...
